Program
WS016
A development code. Also written as “WS016 Single Dose(6g)”, “WS016 Single Dose(12g)” and “WS016 Single Dose(24g)”.
Its studies are mostly in Hyperkalemia, led by Waterstone Pharmaceutical (Wuhan).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Waterstone Pharmaceutical (Wuhan) | 43 open or running | phase 3since Nov 18, 2025 | Feb 3, 2024 | Nov 2026phase 3 · NCT07251309 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 3, 2024First study: phase 2 study in HyperkalemiaFirst studyNCT06277128 · 140 planned · China
- Feb 19, 2024Phase 1 study in HyperkalemiaNCT06281470 · 66 enrolled · China
- Nov 18, 2025Phase 3 study in HyperkalemiaPhase 3 reachedNCT07251309 · 420 planned · China
- Oct 13, 2026Phase 3 study in HyperkalemiaNCT07881965 · 300 planned · China
Ahead
- Nov 2026Primary completion: phase 3 study in HyperkalemiaNCT07251309
- Feb 20, 2029Primary completion: phase 3 study in HyperkalemiaNCT07881965
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07881965Hyperkalemia · China | 3 | Recruiting | Feb 20, 2029 | 300 |
| NCT07251309Hyperkalemia · China | 3 | Recruiting | Nov 2026 | 420 |
| NCT06281470Hyperkalemia · China | 1 | Completed | Jun 15, 2023 | 66 |
| NCT06277128Hyperkalemia · China | 2 | Recruiting | Apr 18, 2024 | 140 |
How it is read
Names in the registry
- “WS016”, 4 entries
- “WS016 Single Dose(6g)”, 1 entry
- “WS016 Single Dose(12g)”, 1 entry
- “WS016 Single Dose(24g)”, 1 entry
- “WS016 Single Dose(36g)”, 1 entry
Codes read as this program: WS016.
Conditions, from the studies’ own filings
- Hyperkalemia, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.